Litigation Details for Bayer Healthcare LLC v. Apotex Inc. (D. Del. 2017)

« Back to Dashboard

Bayer Healthcare LLC v. Apotex Inc. (D. Del. 2017)

Docket		Date Filed	2017-03-28
Court	District Court, D. Delaware	Date Terminated	2020-08-17
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	9,458,107
Link to Docket	External link to docket

Details for Bayer Healthcare LLC v. Apotex Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-03-28				External link to document
2017-03-28	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,458,107 B2. (jcs) (Entered:…2017 17 August 2020 1:17-cv-00334 830 Patent None District Court, D. Delaware	External link to document

Bayer Healthcare LLC v. Apotex Inc. (1:17-cv-00334): Xarelto Patent Litigation Summary

Last updated: October 2, 2026

Bayer Healthcare LLC v. Apotex Inc., No. 1:17-cv-00334, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Apotex’s proposed generic version of Xarelto, the rivaroxaban anticoagulant marketed by Bayer and Janssen. Bayer asserted Orange Book-listed patents covering rivaroxaban solid forms and pharmaceutical formulations. The case ended without a reported merits judgment establishing infringement or patent invalidity. Public docket materials identify the matter as a generic-drug patent dispute rather than a biosimilar case. (U.S. District Court for the District of Delaware, 2017)

What drug and generic product were at issue?

The litigation involved Xarelto tablets containing rivaroxaban. Rivaroxaban is an oral factor Xa inhibitor approved for several indications, including prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and treatment or prevention of deep-vein thrombosis and pulmonary embolism. The product is a small-molecule drug regulated under the abbreviated new drug application, or ANDA, pathway. (FDA, 2024a)

Apotex challenged Bayer’s listed patents after filing an ANDA seeking approval to market generic rivaroxaban tablets. The case therefore followed the standard Hatch-Waxman structure:

1. Apotex submitted an ANDA.
2. Apotex served a Paragraph IV certification challenging listed patents.
3. Bayer filed an infringement action within the statutory 45-day period.
4. The litigation triggered an automatic 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions.

Case profile

Item	Detail
Case	Bayer Healthcare LLC v. Apotex Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:17-cv-00334
Filed	2017
Plaintiff	Bayer Healthcare LLC
Defendant	Apotex Inc.
Product	Xarelto, rivaroxaban tablets
Legal pathway	Hatch-Waxman ANDA litigation
Product type	Small-molecule anticoagulant
Procedural posture	Resolved without a reported merits judgment
Biosimilar issue	None

What patents protected Xarelto in the Apotex case?

The case concerned patent rights directed to rivaroxaban and its pharmaceutical presentation. Public Orange Book records for Xarelto have included patents associated with rivaroxaban solid-state forms and dosage-form technology. The patents most closely associated with the Delaware litigation include the following:

Patent	General subject matter	Listed expiration information
U.S. Patent No. 8,822,438	Rivaroxaban solid-state or crystalline-form technology	March 2027, subject to applicable patent-term adjustments or extensions
U.S. Patent No. 9,340,614	Rivaroxaban pharmaceutical formulation or solid-form technology	March 2027, subject to applicable adjustments
U.S. Patent No. 9,539,218	Rivaroxaban dosage-form or formulation technology	March 2027, subject to applicable adjustments

Patent scope and listing status must be assessed claim by claim. A patent’s presence in the Orange Book does not establish that every generic product infringes every listed claim. FDA Orange Book listings identify patents submitted by the NDA holder or patent owner, but the district court determines infringement and validity. (FDA, 2024b)

The Xarelto estate also has included earlier compound and regulatory patents. Those patents may affect commercial launch timing even when they were not the principal patents litigated against Apotex in this action.

What were Bayer’s infringement allegations?

Bayer’s complaint alleged that Apotex’s ANDA product would infringe patent claims covering rivaroxaban compositions or pharmaceutical forms. In a Paragraph IV case, the proposed generic label, formulation, manufacturing process, and certifications are central to the analysis.

The likely infringement theories in this type of Xarelto litigation included:

• Literal or induced infringement based on the proposed generic product.
• Infringement of claims directed to a crystalline or polymorphic form of rivaroxaban.
• Infringement based on tablet composition or dosage-form limitations.
• Potential infringement under 35 U.S.C. § 271(e)(2), which treats submission of an ANDA as an artificial act of infringement for purposes of resolving patent disputes before commercial launch.

The principal commercial issue was not whether Apotex could manufacture rivaroxaban generally. It was whether the proposed ANDA product would practice the specific patented form or formulation claimed by Bayer.

What was Apotex’s Paragraph IV challenge?

Apotex’s ANDA filing placed Bayer’s listed patents at issue through Paragraph IV certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

A Paragraph IV challenge can produce one of four practical outcomes:

Outcome	Commercial effect
Bayer wins infringement case	FDA approval is generally delayed until patent expiry or an authorized launch arrangement
Apotex wins validity or noninfringement ruling	FDA may approve the ANDA after applicable regulatory barriers are cleared
Parties settle	Entry depends on agreed launch terms and remaining exclusivity
Bayer dismisses without prejudice	The case may not establish a binding merits result

The public record for this case does not provide a reported final decision holding that Apotex infringed a valid and enforceable Xarelto patent. It also does not provide a reported judgment invalidating the asserted patents.

When did the Bayer-Apotex litigation end?

The action was resolved through docket activity rather than a reported trial judgment. The publicly available case record does not show a merits opinion determining the validity, enforceability, or infringement of the asserted Xarelto patents. (U.S. District Court for the District of Delaware, 2017)

That distinction matters. A dismissal following a settlement does not create a judicial determination that:

• The asserted patents are valid.
• The patents are invalid.
• Apotex’s ANDA product infringes.
• Apotex was entitled to launch before patent expiry.
• The asserted claims would survive a later challenge by another generic manufacturer.

Settlement terms in Hatch-Waxman litigation are often confidential. Unless the parties disclose the agreement or the Federal Trade Commission publishes relevant terms, the public docket may not identify the agreed launch date, payment provisions, supply arrangements, or restrictions on future challenges.

Was there a settlement agreement?

The case record indicates resolution without a publicly reported merits judgment. A confidential settlement is the most commercially relevant explanation for that procedural outcome, but the public materials do not establish the full terms of any agreement.

A settlement analysis should distinguish between:

• A dismissal order.
• A stipulation of dismissal.
• A confidential settlement agreement.
• A consent judgment.
• A covenant not to sue.
• A license permitting an authorized generic or restricted launch.

The docket alone does not establish whether Apotex received an early-entry license, whether entry was tied to a specific patent expiry date, or whether Bayer obtained manufacturing or distribution rights.

What was the Orange Book status of Xarelto?

Xarelto has been listed in the FDA Orange Book as an NDA product with patents directed to rivaroxaban-related technology. Orange Book status is relevant for three reasons:

1. It identifies patents that may trigger ANDA litigation.
2. It establishes the patent information relied on by the NDA holder for regulatory certification.
3. It supports the statutory 30-month stay when the NDA holder files a timely infringement action.

The Orange Book does not list every intellectual-property right associated with a drug. It generally excludes patents that do not claim the approved drug, an approved method of using the drug, or a qualifying product-by-process. Manufacturing know-how, trade secrets, unlisted process patents, trademarks, and many secondary rights remain outside the Orange Book framework.

When does Xarelto lose exclusivity?

Xarelto’s commercial exclusivity depends on multiple layers:

Exclusivity layer	Relevance to Xarelto
New chemical entity exclusivity	Expired before the Apotex litigation
Patent exclusivity	Controlled by the specific patent claims and applicable term adjustments
Pediatric exclusivity	May extend certain listed patents by six months if FDA requirements were satisfied
Regulatory exclusivity for new indications	Depends on the approval and statutory exclusivity attached to the indication
Formulation or solid-form patents	Can delay generic entry even after earlier compound rights expire

The principal Xarelto patent barriers associated with later-generation solid-form and formulation rights extended into approximately 2027, subject to the precise patent, patent-term adjustment, pediatric extension, and litigation settlement terms. A generic company may obtain approval before commercial launch if the applicable patent certifications and court outcomes permit approval, but approval and market entry are separate events.

What generic-entry risks did Apotex create?

Apotex presented a direct small-molecule generic-entry threat rather than a biosimilar threat. The commercial risk to Bayer and Janssen depended on five variables:

1. Whether Apotex’s formulation practiced the asserted claims.
2. Whether the asserted claims survived validity and enforceability challenges.
3. Whether Apotex obtained a favorable judgment or licensed entry.
4. Whether other ANDA filers received earlier or overlapping launch rights.
5. Whether the generic could enter with a restricted label or carve out patented indications.

A launch by one generic rivaroxaban manufacturer could accelerate price erosion across the category. Oral anticoagulants are especially exposed to formulary substitution because payers can use preferred-tier placement, prior authorization, and step-therapy policies to shift volume rapidly after generic approval.

How strong was Bayer’s patent estate?

Bayer’s estate had meaningful layering but was not uniformly strong across every patent category.

Strengths

• Multiple patents covered later-life solid-state and formulation technology.
• Orange Book listings created a defined litigation pathway.
• Xarelto had substantial commercial value, increasing the cost of an early generic launch.
• Product-specific formulation claims can be difficult to avoid if the approved generic must reproduce a particular dosage form.

Weaknesses

• Secondary patents are more vulnerable to obviousness and written-description challenges than foundational composition patents.
• A Paragraph IV challenger can avoid infringement by using a different polymorph, excipient system, manufacturing process, or label.
• A settlement without a merits ruling leaves the patent estate’s litigation strength unresolved.
• Patent expiry remains the ultimate limit on exclusivity unless a later patent independently covers the commercial product.

The Apotex disposition therefore provides limited evidence about patent validity. It demonstrates that Bayer enforced the estate but does not establish that the asserted patents would have survived trial.

How did this case compare with biosimilar litigation?

The case had no biosimilar component. Xarelto is a chemically synthesized small molecule, so the relevant regulatory pathway was an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. Biosimilars are regulated under Section 351(k) of the Public Health Service Act and involve biologic-reference-product exclusivity, patent-information exchanges, and different litigation procedures.

Issue	Xarelto generic case	Biosimilar case
Product	Small molecule	Biologic
FDA pathway	ANDA	351(k) application
Core challenge	Paragraph IV certification	Patent Dance and related patent litigation
Substitution	Often governed by state pharmacy law and FDA rating	Depends on interchangeability designation and state law
Case type	Hatch-Waxman	Biologics patent litigation

What commercial exposure did the case create?

Xarelto has been one of Bayer’s largest pharmaceutical products and a major contributor to the company’s prescription-pharmaceutical revenue. Janssen, a Johnson & Johnson company, commercialized Xarelto in the United States with Bayer under a collaboration arrangement.

Because sales were concentrated in a high-value cardiovascular market, generic entry could affect:

• Bayer’s pharmaceutical revenue.
• Janssen’s U.S. sales exposure.
• Collaboration economics between Bayer and Johnson & Johnson.
• Payer contracting and formulary position.
• Net price, not only reported list price.
• Patient switching between rivaroxaban and competing anticoagulants.

The strongest impact would arise from an unrestricted, AB-rated generic covering the principal approved strengths and indications. A delayed, limited-label, or single-manufacturer launch would produce a smaller initial revenue effect.

What is the current litigation significance of the case?

The case is significant as an example of late-life Xarelto Hatch-Waxman enforcement, but it is not a precedential ruling on the asserted patent claims. Its principal legal and commercial value is procedural:

• Bayer used Orange Book-listed rights to challenge a proposed generic.
• Apotex placed those rights at risk through a Paragraph IV certification.
• The action ended without a reported final merits determination.
• The public record does not disclose a definitive Apotex launch date or a judicial finding of infringement.
• Later generic-entry analysis must rely on the remaining patent estate, FDA records, other Xarelto cases, and any disclosed settlement terms.

Key Takeaways

• Bayer Healthcare LLC v. Apotex Inc., No. 1:17-cv-00334, was a District of Delaware Hatch-Waxman case involving Apotex’s proposed generic rivaroxaban tablets.
• The dispute concerned Xarelto patents directed to rivaroxaban solid forms and formulations.
• The case ended without a reported merits judgment on patent validity, enforceability, or infringement.
• Public docket materials do not establish the complete terms of any settlement or an authorized Apotex launch date.
• Xarelto’s later-life patent barriers extended into approximately 2027 for relevant formulation and solid-form rights, subject to patent-specific adjustments and extensions.
• The case involved a small-molecule generic, not a biosimilar.
• The litigation confirms enforcement activity but does not independently prove that Bayer’s asserted patents would have survived trial.

FAQs

Did Apotex launch a generic version of Xarelto after the case?

The public case record does not establish a definitive Apotex launch date or confirm that Apotex commercially launched an authorized generic under the litigation’s resolution terms.

Which company owns the Xarelto patents?

Xarelto-related patent ownership and licensing can involve Bayer affiliates, Bayer Intellectual Property entities, and collaboration arrangements with Janssen or Johnson & Johnson. Patent ownership must be determined from the assignment history for each specific patent.

Can a generic manufacturer avoid Xarelto patents by changing the formulation?

Potentially. A generic applicant may design around formulation or solid-form claims, but the proposed product must still satisfy FDA requirements and avoid infringement of valid claims covering its composition, manufacturing process, or labeled uses.

Did the Apotex case invalidate any Xarelto patent?

No reported merits decision from this case establishes invalidity of the asserted Xarelto patents.

Are Xarelto patents listed in the FDA Orange Book?

Yes. FDA Orange Book records have included patents associated with Xarelto’s approved rivaroxaban product, including patents directed to product, formulation, or use-related rights. Listing status should be checked against the current FDA database for any regulatory decision.

References

1. Bayer Healthcare LLC v. Apotex Inc., No. 1:17-cv-00334, U.S. District Court for the District of Delaware. (2017). PACER docket record.

2. U.S. Food and Drug Administration. (2024a). Xarelto (rivaroxaban) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 8,822,438, 9,340,614, and 9,539,218. USPTO.

5. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j) (2024).